Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205244
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Colet, Josep Comín | - |
dc.contributor.author | Mainar, Antoni Sicras | - |
dc.contributor.author | Salazar-mendiguchía, Joel | - |
dc.contributor.author | Del Campo Alonso, María Isabel | - |
dc.contributor.author | Echeto, Ainara | - |
dc.contributor.author | Larena, David Vilanova | - |
dc.contributor.author | Sánchez, Olga Delgado | - |
dc.date.accessioned | 2024-01-04T17:22:09Z | - |
dc.date.available | 2024-01-04T17:22:09Z | - |
dc.date.issued | 2023-07-25 | - |
dc.identifier.issn | 2042-6313 | - |
dc.identifier.uri | http://hdl.handle.net/2445/205244 | - |
dc.description.abstract | Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of euro274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Becaris Publishing Limited | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.57264/cer-2023-0007 | - |
dc.relation.ispartof | Journal of Comparative Effectiveness Research, 2023, vol. 12, num. 8 | - |
dc.relation.uri | https://doi.org/10.57264/cer-2023-0007 | - |
dc.rights | cc by-nc-nd (c) Colet, Josep Comín et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Medicaments cardiovasculars | - |
dc.subject.classification | Anàlisi cost-benefici | - |
dc.subject.other | Cardiovascular agents | - |
dc.subject.other | Cost effectiveness | - |
dc.title | Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-12T11:18:04Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37489950 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cer-2023-0007.pdf | 1.43 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License